MARKET

THTX

THTX

Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.380
+0.090
+3.93%
After Hours: 2.350 -0.03 -1.26% 17:47 01/20 EST
OPEN
2.320
PREV CLOSE
2.290
HIGH
2.395
LOW
2.230
VOLUME
572.62K
TURNOVER
--
52 WEEK HIGH
3.250
52 WEEK LOW
1.330
MARKET CAP
183.29M
P/E (TTM)
-7.7702
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
National Bank Sticks to Their Hold Rating for Theratechnologies (THTX)
In a report released today, Endri Leno from National Bank maintained a Hold rating on Theratechnologies (THTX), with a price target of C$3.75. The
SmarterAnalyst · 9h ago
DJ Theratechnologies Price Target Is Maintained at C$3.75/Share by National Bank
Dow Jones · 11h ago
DJ Theratechnologies Is Maintained at Sector Perform by National Bank
Dow Jones · 11h ago
Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
GlobeNewswire · 1d ago
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Chr...
GlobeNewswire · 6d ago
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
GlobeNewswire · 6d ago
RBC Capital Keeps a Hold Rating on Theratechnologies (THTX)
In a report issued on January 7, Brian Abrahams from RBC Capital maintained a Hold rating on Theratechnologies (THTX), with a price target of $2.00. The
SmarterAnalyst · 6d ago
ACRX, ZOM, DDD and JAGX among midday movers
Gainers: ArcLight Clean Transition (ACTCU) +80%.VOXX International (VOXX) +47%.BIOLASE (BIOL) +43%.Dolphin Entertainment (DLPN) +41%.ENGlobal (ENG) +39%.Zomedica (ZOM) +39%.IRIDEX (IRIX) +34%.AcelRx Pharmaceuticals (ACRX) +28%.La Jolla Pharmaceutical (LJPC) +25%.Tyme Technologies (TYME) +24%.Losers: LM Funding America (LMFA) -19%.Isoray (ISR) -16%.Theratechnologies (THTX) -16%.Enveric Biosciences (ENVB) -14%.Jaguar
Seekingalpha · 01/12 17:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of THTX. Analyze the recent business situations of Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average THTX stock price target is 4.000 with a high estimate of 6.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 4.83M
% Owned: 6.27%
Shares Outstanding: 77.01M
TypeInstitutionsShares
Increased
7
191.79K
New
9
-102.67K
Decreased
9
58.51K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.19%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Director
Dawn Svoronos
President/Chief Executive Officer/Director
Paul Levesque
Chief Financial Officer/Senior Vice President/IR Contact Officer
Philippe Dubuc
Senior Vice President
Jovan Antunovic
Senior Vice President
Christian Marsolais
Vice President - Finance
Marie-Noel Colussi
Vice President/Secretary
Jocelyn Lafond
Vice President
Denis Boucher
General Manager
Conor Walshe
Independent Director
Sheila Frame
Independent Director
Gerald Lacoste
Independent Director
Gary Littlejohn
Independent Director
Andrew Molson
Independent Director
Paul Pommier
Independent Director
Alain Trudeau
Independent Director
Dale Weil
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About THTX
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.
More

Webull offers kinds of Theratechnologies Inc stock information, including NASDAQ:THTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading THTX stock methods without spending real money on the virtual paper trading platform.